Werewolf Therapeutics, Inc.
HOWLAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 19, 2025 | Wedbush | $1.00(+45%) | $0.69 | TheFly | |
| Apr 3, 2024 | JMP Securities | Reni Benjamin | $12.00(+98%) | $6.06 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Dec 19, 2025 |
| Wedbush | downgrade | Outperform →Neutral | Dec 19, 2025 |
| B of A Securities | maintain | Buy | Nov 18, 2025 |
| B of A Securities | maintain | Buy | Aug 25, 2025 |
| JMP Securities | maintain | Market Outperform | Aug 21, 2025 |
| Wedbush | maintain | Outperform | May 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 12, 2025 |
| Wedbush | maintain | Outperform | Mar 12, 2025 |
| JMP Securities | maintain | Market Outperform | Jan 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 26, 2024 |
| JMP Securities | maintain | Market Outperform | Jun 26, 2024 |
| JMP Securities | maintain | Market Outperform | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2024 |
| JMP Securities | maintain | Market Outperform | May 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 19, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2023 |
| HC Wainwright& Co. | maintain | Buy | Aug 10, 2023 |
Earnings History
Next report: Mar 25, 2027 · EPS est. $-0.17| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Jul 31, 2026 | $0.08 | $-0.28 | $21.0M | $21.0M |
| May 7, 2026 | $-0.28 | $-0.32 | — | — |
| Mar 27, 2026 | $-0.20 | $-0.34 | — | $300.0K |
| Nov 4, 2025 | $-0.36 | $-0.39 | — | — |
| Aug 14, 2025 | $-0.40 | $-0.50 | — | — |
| May 8, 2025 | $-0.40 | $-0.44 | — | $375.0K |
| Mar 11, 2025 | $-0.46 | $-0.43 | — | $301.6K |
| Nov 7, 2024 | $-0.38 | $-0.41 | — | $709.3K |
News
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting, taking place …
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LITE, HOWL, PERI, GSBD and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 9th, 2026.
Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have been assigned an average rating of "Hold" from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating
BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 2026
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon clos
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon closing of the proposed transaction, Werewolf shareholders are expected to own approximately 6.8% of the combined company.Halper Sadeh encourages Werewolf shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halper…
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire
Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the company has agreed to a definitive all-stock merger with Ambros Therapeutics. The combined company will pivot to focus on Ambros' Phase 3 drug candidate – neridronate – for Complex Regional Pain Syndrome Type 1 (CRPS-1), backed by an oversubscribed $150 million private placement from top-tier institutional investors like RA Capital and Janus Henderson.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was one of the market's biggest pre-market movers on Friday after announcing a merger with Ambros Therapeutics.
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics' neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combi…